Clinical trials: Diuretics Resistance
Hypertension
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00364026
- Testing
- darusentan
- Sponsor
- Gilead Sciences
Heart Failure, Acute Heart Failure
Protocol of Diuretics Use in Congestive Therapy in Heart Failure
The main objective of the study is to determine if a diuretic adaptation protocol in the decompensation of chronic heart failure is more effective but also safer than the current non-protocolized practice.
- Conditions
- Heart Failure, Acute Heart Failure, Chronic Heart Failure
- Trial name
- ProDUCT-HF (NCT03892148)
- Testing
- Furosemide, Hydrochlorothiazide
- Where
- 9 sites in France
- Volunteers
- 299 people
- Sponsor
- University Hospital, Clermont-Ferrand
Heart Failure
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures.
- Trial name
- MsDR (NCT05323487)
- Testing
- Bumetanide Injection
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Yale University
Heart Failure
DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance
To assess the effect of dapagliflozin compared with metolazone, added to furosemide, on diuresis and decongestion in hospitalised heart failure patients with diuretic resistance, and renal impairment.
- Trial name
- DAPARESIST (NCT04860011)
- Testing
- Dapagliflozin 10 MG Oral Tablet, Metolazone Tablets
- Where
- 2 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- NHS Greater Glasgow and Clyde
Heart Failure
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure
Effective diuresis is the primary goal of most acute decompensated heart failure hospitalizations, but diuretic resistance is common and our ability to detect it is limited.
- Trial name
- NCT02546583
- Testing
- Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide), IV Chlorothiazide
- Where
- United States
- Volunteers
- 458 people
- Sponsor
- Yale University
Hypertension
Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
Thiazide medications are often prescribed for individuals with high blood pressure, but research has shown that they may increase an individual's risk of developing diabetes.
- Trial name
- NCT00353652
- Testing
- Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose
- Where
- 2 sites in United States
- Volunteers
- 166 people
- Sponsor
- University of Texas Southwestern Medical Center
Hypertension
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00330369
- Testing
- Darusentan
- Where
- 115 sites in United States, Argentina and 9 more
- Volunteers
- 352 people
- Sponsor
- Gilead Sciences
Acute Heart Failure, Diuretic Resistance
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
The P-VALUE-AHF trial is a multicenter, randomized, open-label, parallel-group trial on the diuretic and decongestive effects of different diuretic escalation strategies in patients with acute heart failure and diuretic…
- Trial name
- P-Value-AHF (NCT05986773)
- Testing
- Furosemide, Metolazone, Acetazolamide
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Stadtspital Zürich
Ascites
Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance
To investigate the safety and performance of the Automated Fluid Shunt in patients with ascites and diuretic resistance. Study Size and Duration The primary study population will include 40 patients enrolled and implanted with…
- Trial name
- PIONEER (NCT01030185)
- Testing
- NovaShunt's Automated Fluid Shunt implantation
- Where
- 9 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 40 people
- Sponsor
- NovaShunt AG
After Cardiac Surgery, Diuretic Resistance
Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery
evaluation of the efficacy of recombinant human brain natriuretic peptide in patients with diuretic resistance after cardiac surgery: a prospective single-center single-blind randomized controlled study
- Trial name
- rhBNP (NCT07086287)
- Testing
- rhBNP and standard basic treatment
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Heart Failure
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
This is a prospective, single-center, double-blind and randomized placebo controlled trial for evaluation of a 7-day 100mg daily dose of spironolactone on weight loss and resolution of signs and symptoms of congestion in…
- Trial name
- NCT02585843
- Testing
- Spironolactone 100mg, Spironolactone 25mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Heart Failure
High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure
Prospective, open-label, randomized cohort study comparing adding high-dose spironolactone to usual heart failure care versus usual care in patients with acute decompensated heart failure.
- Trial name
- NCT02429388
- Testing
- Spironolactone
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hypertension
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot…
- Trial name
- Darusentan (NCT00353574)
- Testing
- Darusentan
- Where
- 75 sites in United States, Argentina and 6 more
- Volunteers
- 282 people
- Sponsor
- Gilead Sciences
Heart Failure, Volume Overload
Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0
This study is a multi-center, prospective, randomized (2:1), open-label study to evaluate the safety and efficacy of DSR therapy using the Infusate 2.0 peritoneal solution (composed of 30% icodextrin and 10% dextrose) in diuretic…
- Trial name
- MOJAVE (NCT05965934)
- Testing
- Direct Sodium Removal Infusate 2.0
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sequana Medical N.V.
Acute Heart Failure, Acute Kidney Injury
Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study
This study aims to demonstrate the efficacy of sequential nephron blockade by adding hydrochlorothiazide or spironolactone on intravenous furosemide compared to intravenous furosemide alone in the treatments of volume overload in…
- Trial name
- NEB-HF (NCT04465123)
- Testing
- Spironolactone or hydrochlorothiazide
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chiang Mai University
Hypertension
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor…
- Trial name
- Darusentan (NCT00389675)
- Testing
- Darusentan, Guanfacine
- Where
- 99 sites in United States, Argentina and 2 more
- Volunteers
- 661 people
- Sponsor
- Gilead Sciences
Cardio-Renal Syndrome
Kidney Sodium Content in Cardiorenal Patients
Diuretic therapy is the cornerstone of the management of fluid overload in heart failure. Resistance to diuretic therapy is the most common reason for treatment failure in patients affected by the combination of heart failure and…
- Trial name
- NCT04170855
- Testing
- Furosemide Injection
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Acute Decompensated Heart Failure, Diuretics Resistance
Exploring Diuretics Effective Management in Acute Decompensated Heart Failure, EDEMA Trial
1. Evaluate efficacy and safety of continuous infusion of IV Frusemide compared to IV shots in acute decompensated heart failure ADHF 2.
- Trial name
- EDEMA (NCT03863626)
- Testing
- Frusemide IV shots, Frusemide IV infusion
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Cairo University
Heart Failure
Percutaneously Delivered Automated Continual Fluid Removal System in Patients With Advanced Diuretic-Resistant Heart Failure
The study aims to assess the feasibility, safety, tolerability and functionality of a percutaneously delivered automated continual fluid removal System in up to 8 patients with Heart Failure (HF) and diuretic resistance.
- Trial name
- CLEAR-HF (NCT06689553)
- Testing
- Automated Continual Fluid Removal System
- Where
- 3 sites in Serbia, Spain
- Volunteers
- 2 people
- Sponsor
- Paragate Medical LTD
Insulin Resistance
The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride
Thiazolidinedione derivates (TZD's) are Peroxisome-Proliferator-Activated-Receptor-γ agonists (PPARγ-agonists) and enhance insulin sensitivity.
- Trial name
- NCT00285805
- Testing
- response (sodium excretion) to amiloride infusion, response (sodium excretion) to furosemide infusion
- Where
- Netherlands
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center